Literature DB >> 3672421

Plasma kallikrein-kinin system in patients with uncomplicated sepsis and septic shock--comparison with cardiogenic shock.

F Martínez-Brotóns1, J R Oncins, J Mestres, V Amargós, C Reynaldo.   

Abstract

Alterations of the kallikrein-kinin system consistent with activation and increased consumption have been reported in septic patients and it has been suggested that this activation could contribute to the development of septic shock. The aim of this work was to confirm these alterations in septic patients and to investigate the possible existence of similar changes in subjects developing cardiogenic shock secondary to myocardial infarction as a model of non septic shock. Patients with septic shock, especially in fatal cases, showed a highly significant decrease in levels of factor XII, prekallikrein, high molecular weight kininogen (HMW-kininogen), alpha 2-macroglobulin (alpha 2-M) and antithrombin III (AT-III). C1-esterase inhibitor (C1-INH) activity was increased in uncomplicated sepsis but came back to normal or was slightly decreased in septic shock. Components and inhibitors of the kallikrein-kinin system were within normal limits in patients with cardiogenic shock. Our findings support the idea of a contribution of the kallikrein-kinin system to the development of septic shock though this system does not seem to play a significant role in the pathogenesis of cardiogenic shock or seem to be altered as a consequence of it.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3672421

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 2.  The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis.

Authors:  R W Colman; R B Sartor; A A Adam; R A DeLa Cadena; A Stadnicki
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Cleavage of plasma high molecular weight kininogen in surgical ICU patients.

Authors:  T S Karlsrud; L Buø; A O Aasen; H T Johansen
Journal:  Intensive Care Med       Date:  1996-08       Impact factor: 17.440

4.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Relationship between angiotensinogen, alpha 1-protease inhibitor elastase complex, antithrombin III and C-reactive protein in septic ARDS.

Authors:  U Hilgenfeldt; W Kellermann; G Kienapfel; M Jochum
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Effects of aprotinin on hemorrhagic complications in ARDS patients during prolonged extracorporeal CO2 removal.

Authors:  F Brunet; J P Mira; M Belghith; J J Lanore; S Schlumberger; P Toulon; J F Dhainaut
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

8.  Heparin clearance during continuous veno-venous haemofiltration.

Authors:  M Singer; T McNally; G Screaton; I Mackie; S Machin; S L Cohen
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

Review 9.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

10.  Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.

Authors:  My-Linh Ngo; Fakhri Mahdi; Dhaval Kolte; Zia Shariat-Madar
Journal:  J Inflamm (Lond)       Date:  2009-01-27       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.